Amphastar Pharmaceuticals (AMPH) to Release Earnings on Wednesday

Key Points

• Q1 2026 earnings are due after the market close on Wednesday, May 6, 2026 (conference call at 5:00 PM ET), with analysts expecting $0.70 EPS and $174.09M in revenue.
• The company missed the prior quarter's estimates (EPS $0.73 vs. $0.97 consensus; revenue $183.11M vs. $190.48M), and Wall Street sentiment has been trimmed to a consensus "Hold" with an average price target of $27.43 after several downgrades.
• Amphastar has a market cap of roughly $971.8M, a PE of 10.75 and a 12‑month range of $17.03–$31.26, with institutional investors owning about 65% of the stock.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.70 per share and revenue of $174.0890 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.24). The firm had revenue of $183.11 million during the quarter, compared to the consensus estimate of $190.48 million. Amphastar Pharmaceuticals had a return on equity of 17.58% and a net margin of 13.63%. On average, analysts expect Amphastar Pharmaceuticals to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $21.82 on Wednesday. The firm has a 50-day moving average price of $21.32 and a 200-day moving average price of $24.59. The firm has a market capitalization of $971.75 million, a PE ratio of 10.75, a price-to-earnings-growth ratio of 1.75 and a beta of 0.92. The company has a current ratio of 4.02, a quick ratio of 2.90 and a debt-to-equity ratio of 0.77. Amphastar Pharmaceuticals has a 12-month low of $17.03 and a 12-month high of $31.26.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Needham & Company LLC reduced their price target on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, February 27th. Wells Fargo & Company reduced their price target on shares of Amphastar Pharmaceuticals from $34.00 to $30.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Weiss Ratings downgraded shares of Amphastar Pharmaceuticals from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, April 10th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Barclays reduced their price target on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Hold" and an average price target of $27.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC increased its position in Amphastar Pharmaceuticals by 2.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 19,397 shares of the company's stock valued at $478,000 after purchasing an additional 459 shares during the period. Advisory Research Inc. increased its position in Amphastar Pharmaceuticals by 3.8% during the 3rd quarter. Advisory Research Inc. now owns 15,468 shares of the company's stock valued at $412,000 after purchasing an additional 570 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Amphastar Pharmaceuticals by 2.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock valued at $652,000 after purchasing an additional 613 shares during the period. Janney Montgomery Scott LLC increased its position in Amphastar Pharmaceuticals by 6.2% during the 4th quarter. Janney Montgomery Scott LLC now owns 14,230 shares of the company's stock valued at $381,000 after purchasing an additional 825 shares during the period. Finally, Commonwealth Equity Services LLC increased its position in Amphastar Pharmaceuticals by 11.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company's stock valued at $234,000 after purchasing an additional 882 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.